| Active Not Recruiting | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients NCT02835222 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia NCT03009240 | City of Hope Medical Center | Phase 1 |
| Completed | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950 | Mayo Clinic | Phase 2 |
| Completed | Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia NCT02581917 | Wake Forest University Health Sciences | — |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations NCT02323607 | Bhavana Bhatnagar | Phase 1 |
| Terminated | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut NCT02634827 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495 | City of Hope Medical Center | Phase 1 |
| Withdrawn | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With N NCT02472626 | Wake Forest University Health Sciences | Phase 1 / Phase 2 |
| Completed | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Mye NCT02583893 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hema NCT02122081 | Sumithira Vasu | Phase 1 |
| Completed | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid NCT01806571 | Mayo Clinic | Phase 2 |
| Terminated | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML NCT01849276 | Northwestern University | Phase 1 |
| Terminated | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute My NCT02029417 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk My NCT02121418 | University of Washington | N/A |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Ac NCT02096055 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02093403 | Bhavana Bhatnagar | Phase 1 |
| Terminated | AML Therapy With Irradiated Allogeneic Cells NCT02105116 | Rutgers, The State University of New Jersey | N/A |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed o NCT02044796 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia NCT01907815 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia NCT01798901 | Alison Walker | Phase 1 |
| Terminated | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia NCT01876953 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Le NCT01869777 | Wake Forest University Health Sciences | N/A |
| Completed | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acut NCT01804101 | Fred Hutchinson Cancer Center | N/A |
| Completed | Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodyspla NCT01831232 | Fred Hutchinson Cancer Center | N/A |
| Completed | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01822015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Terminated | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia NCT01801046 | University of Southern California | Phase 1 |
| Completed | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating NCT01802333 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With NCT01519596 | Wake Forest University Health Sciences | N/A |
| Unknown | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML NCT01690065 | Ulsan University Hospital | Phase 2 |
| Completed | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leuk NCT01839240 | University of Chicago | Phase 1 |
| Completed | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloi NCT01567059 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients NCT01633099 | Jianxiang Wang | Phase 3 |
| Terminated | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy NCT01521936 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia NCT01555268 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies NCT01564277 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT01361464 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemother NCT01307579 | Children's Oncology Group | Phase 3 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating NCT01349972 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Old NCT02085408 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS NCT01141725 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Adva NCT01101880 | University of Washington | Phase 2 |
| Completed | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01130506 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745 | University of Nebraska | Phase 2 |
| Completed | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodyspl NCT01041443 | City of Hope Medical Center | Phase 1 |
| Completed | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Pr NCT01031368 | Nohla Therapeutics, Inc. | Phase 1 |
| Completed | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia NCT01093573 | Brenda Cooper, MD | Phase 1 / Phase 2 |
| Completed | Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia NCT02144675 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00795002 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Le NCT00742625 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia NCT00703300 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High- NCT00475150 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukem NCT00673153 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid L NCT00602771 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia NCT00492401 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Tre NCT00801489 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myelo NCT00462605 | National Cancer Institute (NCI) | Phase 2 |
| Completed | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplast NCT00459212 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Completed | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute NCT00416598 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00407966 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Ph NCT00383474 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia NCT00352365 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PXD101 in Treating Patients With Acute Myeloid Leukemia NCT00357032 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgki NCT00275080 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myeloge NCT00278330 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00112853 | National Cancer Institute (NCI) | Phase 1 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | XK469R in Treating Patients With Refractory Hematologic Cancer NCT00095797 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid NCT00096148 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00101296 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or NCT00096122 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia NCT00093418 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previo NCT00079378 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Ac NCT00085124 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00049582 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia NCT00039117 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia NCT00027872 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer NCT00012376 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia NCT00016016 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 i NCT00006363 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed NCT00008177 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin W NCT00003934 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloi NCT00003190 | National Cancer Institute (NCI) | Phase 3 |